Photo taken from Sabine Brookman-May/LinkedIn
Feb 21, 2024, 18:28
Sabine Brookman-May: TAR-200 was safe and well tolerated, with encouraging preliminary efficacy in IR
Sabine Brookman-May, Professor of Urology at the Ludwig-Maximilians University of Munchen, posted on X/Twitter:
“Finally out: results of the legacy phase 1b study which built the groundwork for our ongoing phase 2 + 3 studies with the intravesical gemcitabine releasing system TAR-200.
TAR-200 was safe and well tolerated, with encouraging preliminary efficacy in IR.”
Source: Sabine Brookman-May/X